|
|
GI Effects Stool Profiles*
– the latest advancement in stool analysis for truly comprehensive results.
GI Effects is unlike any other stool analysis profile, going beyond the standard parameters for identifying gastrointestinal disorders. GI Effects use DNA analysis to identify microbiota with 100% accuracy including anaerobes, a previously immeasurable area of the gut environment.
Why Should You Switch to the GI Effects Stool Profile?
• Single Sample Collection: GI Effects requires only one collection. This means better compliance and a faster result!
• Greater Accuracy: GI Effects uses DNA analysis to improve the accuracy of your results. It also identifies anaerobes, which are unavailable by culture technique.
• Increased Sensitivity: Detects as few as 5 cells per gram– a 5000-fold increase in sensitivity over old stool technology.
• Better Value: All the components of traditional tests, plus pathogens and more at no additional charge.
Continuing our commitment to innovation…
With advanced technology and revolutionary testing
“PCR is the best developed and most widely used nucleic acid amplification strategy...These techniques have sensitivity unparalleled in laboratory medicine, have created new opportunities for the clinical laboratory to have an effect on patient care and have become the new “gold standards” for laboratory diagnosis of several infectious diseases.”
Manual of Clinical Microbiology, 8th Edition, Vol. 1, page 235, 2003.
More on GI Effects:
*Profile not available in New York
|
|
|
Why Use Stool Testing?
Gastrointestinal Function is important for general health. This includes finding a balance between beneficial microbial flora in the gut to enhance health benefits. GI health is key in digestion, nutrient usage, and ridding the body of waste and pathogens. Poor digestion and malabsorption can lead to immune function disorders, nutritional insufficiencies, and disease state. Poor GI function can lead to food allergies and other toxicities.
Your intestinal tract contains significant amounts of bacteria, some beneficial, some neutral, and some that can be harmful. It is essential to know the microbial balance of your GI tract, especially if you have chronic health problems. Health enhancing intestinal bacteria serve to prevent the overgrowth of potentially harmful bacteria in the gut.
|
|
Clinician Info
| Test name: |
2100** - GI Function Profile
2105** - Microbial Ecology Profile
2110** - Mycology Profile
2115** - Parasitology Profile
**Profiles not available in New York
|
|
|
| Description: |
GI Effects Stool Analysis Profiles go beyond "old stool technology" to bring you the most comprehensive stool analysis to date. GI Effects Profiles use DNA analysis to identify microbiota with 100% accuracy — including anaerobes, a previously immeasurable area of the gut environment. In addition to much more comprehensive bacteriology, mycology, and parasitology, GI Effects Profiles report drug resistance genes, antibiotic and botanical sensitivities, gliadin-specific sIgA, Elastase1, plus other inflammation, digestion, and absorption markers clinicians requested — with no hidden costs.
|
|
|
| Method: |
GC/MS, PCR ELISA, Automated Chemistry, Colorimetric, HPLC |
|
|
| Turnaround time: |
10 - 14 days |
|
|
|
Analytes:
|
BENEFICIAL BACTERIA
Obligate anaerobes
Bacteroides sp.
Clostridia sp
Prevotella sp.
Fusobacteria sp.
Streptomyces sp.
Mycobacteria sp.
Eubacteria sp.
Facultative anaerobes
Lactobacillus
Bifidobacter
Obligate aerobes
E. coli
OPPORTUNISTIC BACTERIA
Aerobes
Klebsiella pneumoneae
Bacillus sp.
Citrobacter freundii
Haemolytic E. coli.
Psuedomonas sp.
plus many others
PATHOGENS
Pathogenic Bacteria
H. pylori
C. difficile
Campylobacter
E.H.E. coli
Pathogenic Parasites
Entamoeba histolytica
Giardia lamblia
Cryptosporidia
MYCOLOGY
PARASITOLOGY
ADIPOSITY INDEX
Firmicutes
Bacteroidetes
DRUG RESISTANCE GENES
BENEFICIAL SCFA
Total SCFA
n-Butyrate
Acetate %
Butyrate %
Propionate %
Valerate %
INFLAMMATION
Lactoferrin
WBC’s
Mucus
IMMUNOLOGY
Fecal sIgA
Anti-gliadin IgA
ADDITIONAL TESTS
pH
Occult Blood
RBC’s
Color
DIGESTION
Elastase1
Triglycerides
Putrifactive SCFA
Vegetable Fibers
ABSORPTION
LCFA’s
Total Fat
Cholesterol
|
|
CPT codes:
| 87640 |
- |
Staphylococcus aureus, amplified probe |
| 87651 |
- |
Streptococcus, grp A, amplified probe technique |
| 87652 |
- |
Streptococcus, grp A, quantification |
| 87653 |
- |
Streptococcus, grp B, amplified probe technique |
| 87798 x10** |
- |
Infectious agent detection by nucleic acid not
otherwise specified, amplified probe technique
|
| 87799 x10** |
- |
Infectious agent detection by nucleic acid not otherwise
specified, quatification, each organism
|
| 87900 |
- |
Infectious agent drug susceptibility phenotype
prediction by, genotypic bioinformatics
|
| 87186 |
- |
Suseptibility studies, microdilution, each multi-antimicrobial, per plate
|
| 89055 |
- |
Leukocyte, fecal, semiqualitative* |
| 82715 |
- |
Cholesterol, Stool* |
| 82725 |
- |
Long Chain Fatty Acids, stool* |
| 82270 |
- |
Occult Blood* |
| 83986 |
- |
pH, Stool* |
| 82492 |
- |
Short Chain Fatty Acids, stool* |
| 84478 |
- |
Triglycerides, stool* |
| 82656 |
- |
Elastase, pancreatic, fecal, qualitative* |
| 83631 |
- |
Lactoferrin, fecal, semi-quantitative* |
| 82784 |
- |
Secretory IgA* |
|
|
**Additional infectious agents could include: (under codes 87798 and 87799 above) |
|
|
H. pylori |
|
|
C. difficile |
|
|
Shigella |
|
|
Salmonella |
|
|
E. coli 0157 |
|
|
Cryptosporidium |
|
|
Giardia |
|
|
Entamoeba histolytica |
|
|
Entamoeba dispar |
|
|
Enterohemorrhagic E.coli (EHEC) |
|
|
Campylobactor sp. |
|
|
|
|
|
*Test #2100 only |
|
| |
|
|
Identification of dominant bacteria in feces and colonic mucosa from healthy Spanish adults by culturing and by 16S rDNA sequence analysis.
Delgado S, Suarez A, Mayo B. Dig Dis Sci. 2006;51(4):744-751.
Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR.
Malinen E, Rinttilä T, Kajander K, Mättö J, Kassinen A, Krogius L, Saarela M, Korpela R, Palva A. Am J Gastroenterol. 2005 Feb;100(2):373-82.
Laboratory diagnostic techniques for entamoeba species.
Fotedar R, Stark D, Beebe N, Marriott D, Ellis J, Harkness J. Clin Microbiol Rev. 2007 Jul;20(3):511-32.
Multiplex real-time PCR assay for detection of Entamoeba histolytica, Giardia intestinalis, and Cryptosporidium spp.
Haque R, Roy S, Siddique A, Mondal U, Rahman SM, Mondal D, Houpt E, Petri WA Jr Am J Trop Med Hyg. 2007 Apr;76(4):713-7.
A probiotic treatment containing Lactobacillus, Bifidobacterium and Enterococcus improves IBS symptoms in an open label trial.
Fan YJ, Chen SJ, Yu YC, Si JM, Liu B. J Zhejiang Univ Sci B. 2006 Dec;7(12):987-91.
Mixtures of SCFA, composed according to physiologically available concentrations in the gut lumen, modulate histone acetylation in human HT29 colon cancer cells.
Kiefer J, Beyer-Sehlmeyer G, Pool-Zobel BL. Br J Nutr. 2006 Nov;96(5):803-10.
Molecular analysis of jejunal, ileal, caecal and recto-sigmoidal human colonic microbiota using 16S rRNA gene libraries and terminal restriction fragment length polymorphism.
Hayashi H, Takahashi R, Nishi T, Sakamoto M, Benno Y. J Med Microbiol. 2005 Nov;54(Pt 11):1093-101.
Comparison of PCR and microscopy for detection of Cryptosporidium parvum in human fecal specimens: clinical trial.)
Thompson RC, Morgan UM, Pallant L, Dwyer BW, Forbes DA, Rich G, J Clin Microbiol. 1998 Apr;36(4):995-8.
Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease.
Walker TR, Land ML, Kartashov A, Saslowsky TM, Lyerly DM, Boone JH, Rufo PA.
J Pediatr Gastroenterol Nutr. 2007 Apr;44(4):414-22.
|
|
